Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THULITE trial of oral BI1815368 in center-involving diabetic macular edema
CTR20254165Phase 2Active
- Sponsor
- Boehringer Ingelheim
- Start
- May 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BI1815368 in diabetic macular edema (DME), sponsored by Boehringer Ingelheim. Started May 2026; status: active.
02
Drugs
BI1815368
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20254165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254165.